These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10155329)

  • 1. Clinical and economic considerations in the use of third-generation oral cephalosporins.
    Chambers ST; Murdoch DR; Pearce MJ
    Pharmacoeconomics; 1995 May; 7(5):416-27. PubMed ID: 10155329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
    Perry CM; Scott LJ
    Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
    Fulton B; Perry CM
    Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.
    Davis R; Bryson HM
    Pharmacoeconomics; 1994 Sep; 6(3):249-69. PubMed ID: 10155268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.
    Bijie H; Kulpradist S; Manalaysay M; Soebandrio A
    J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment.
    Hedrick J
    Paediatr Drugs; 2003; 5 Suppl 1():35-46. PubMed ID: 14632104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefdinir: an expanded-spectrum oral cephalosporin.
    Guay DR
    Ann Pharmacother; 2000 Dec; 34(12):1469-77. PubMed ID: 11144705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on treating uncomplicated skin and skin structure infections.
    Rosen T
    J Drugs Dermatol; 2005; 4(6 Suppl):s9-14. PubMed ID: 16300224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential therapy with intravenous and oral cephalosporins.
    Janknegt R; van der Meer JW
    J Antimicrob Chemother; 1994 Jan; 33(1):169-77. PubMed ID: 8157558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical review of the new oral cephalosporins. Considerations and place in therapy.
    Rodman DP; McKnight JT; Anderson RL
    Arch Fam Med; 1994 Nov; 3(11):975-80. PubMed ID: 7804480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community-acquired upper respiratory tract infections and the role of third-generation oral cephalosporins.
    Hedrick JA
    Expert Rev Anti Infect Ther; 2010 Jan; 8(1):15-21. PubMed ID: 20014898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Frampton JE; Brogden RN; Langtry HD; Buckley MM
    Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin.
    Guay DR
    Pediatr Infect Dis J; 2000 Dec; 19(12 Suppl):S141-6. PubMed ID: 11144395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Bryson HM; Brogden RN
    Drugs; 1993 Apr; 45(4):589-621. PubMed ID: 7684677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.